Company was ranked fourth in the sector

Sao Paulo, July 4th, 2017 - Eurofarma achieved the fourth position among the most innovative pharmaceutical companies in Brazil, according to the Valor Inovação Brasil 2017 ranking, conducted by the Valor Econômico newspaper in partnership with Strategy & PWC consultancy company. The event was held on Monday evening, July 3rd, in the city of São Paulo, and awarded the five most innovative companies from 18 different industry sectors.

In recent years, Eurofarma has been consistently investing in the scientific methodologies usage within the Research and Development (R & D) department, including the design of experiments and statistical analysis for the definition of formulations and processes. Investing 6% of its net sales in this segment, the company has to 176 in the pipeline and an expressive number of licenses and approvals, expecting to launch more than 20 products in 2017. “Eurofarma’s R&D expertise and efficiency put the company among the largest pharmaceutical companies in the country, the company with the best performance in portfolio renewal. In addition, we invested R$ 60 million in constructing a Research and Development Center for Eurofarma, which will house several projects related to important innovations, findings, biotechnology, biosimilars and new technology platforms, "says Martha Penna, Innovation Vice-President at Eurofarma.

With a larger number of companies participating in this edition, the Valor Inovação Brasil ranking brought the 150 most innovative companies in Brazil. The ranking evaluated company groups from different sectors according to their investments in innovation, best practices, new products, solutions, strategies, and other indicators.

About Eurofarma Group


Eurofarma Group is the first Brazilian pharmaceutical multinational company with 100% national capital. Recognized by the medical community and society for promoting access to health and life quality with fair price treatments, quality and innovation, the company is present in 20 countries.

Existing for 45 years and 6,500 has collaborators, it has stood out in the segments in which it operates: Medical Prescription and OTC Drugs, Generic Drugs, Hospital, Bids, Oncology, Veterinary and Outsourced Services. Its portfolio includes more than 280 products and in 2016, more than 290 million drugs units were produced. Last year, the Group reached a R$ 3.3 billion revenues, 15.7% higher than the previous year.

In 2016, with investments of R$ 141 million and with its expertise and agility in R & D processes, it has become the pharmaceutical company with the best performance in portfolio renewal, with 176 projects in the pipeline today.

For more information, visit www.eurofarma.com.br

Information to the Press
G&A Relações Públicas - Clareane Moraes | (11) 3065-3045 | clareane@gaspar.com.br
Guilherme Gaspar | (11) 3065-3049 | guilherme@gaspar.com.br